Company intelligence / Profile preview

Hasten Biopharmaceuticals

Hefei, Anhui, China

Ownership: Private
Development stage: Other

Overview

Hasten is actively commercializing established chronic and cardiovascular disease therapies across Asia-Pacific, and developing late-stage assets such as Lerodalcibep (PCSK9 inhibitor) for lowering LDL-cholesterol; extensive pipeline expansion through strategic acquisitions from Takeda and Celltrion, with bridging studies ongoing in China for new approvals[2][5][8].

Therapeutic areas: EndocrinologyMetabolic DisordersCardiovascular
Modalities: Small moleculeFusion proteinProtein
Industry: Biotech

Partnerships

Takeda (licensing of 5 cardiovascular & metabolism drugs)[4]Celltrion (acquisition of 14 branded products across Pan-Asia)[5][8]LIB Therapeutics (Lerodalcibep development/commercialization in China)[2][6]

Beyond the preview

Go deeper on Hasten Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hasten Biopharmaceuticals.

Explore the full profile